NASDAQ · Biotechnology

Oculis Holding AG (OCS) Stock

$8.34 -3.70% NASDAQ: OCS Healthcare

Valuation

MetricValue
Price$8.34
Market Cap$476.79M
P/E Ratio-5.17
P/B Ratio2.02
P/S Ratio1702.08
EPS (TTM)$-1.81
52-Week High$34.48
52-Week Low$8.34
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-42.92%
ROA-31.82%
ROCE-39.20%
Gross Margin-28.89%
Operating Margin-167.41%
Net Margin-188.61%
Debt/Equity0.01
Current Ratio5.92

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$1.0M$0
Operating Profit$-13.0M$-32.0M$-81.0M$-73.0M$-79.0M
Net Profit$-19.0M$-39.0M$-89.0M$-86.0M$-95.0M
EPS$-0.57$-1.18$-2.97$-2.12$-1.81
Op Margin———-10671.1%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$58.0M$37.0M$114.0M$120.0M$236.0M
Total Liabilities$119.0M$135.0M$21.0M$47.0M$40.0M
Cash$46.0M$20.0M$38.0M$28.0M$81.0M
Borrowings$114.0M$123.0M$1.0M$1.0M$2.0M

Latest News

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities GlobeNewswire · Jul 8, 2026 Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference GlobeNewswire · Jul 2, 2026 Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 GlobeNewswire · Jun 11, 2026 Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease GlobeNewswire · Jun 9, 2026 Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference GlobeNewswire · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$-25.0M$-54.0M$-47.0M$-62.0M
Investing Cash Flow$0$-7.0M$-54.0M$-18.0M$-60.0M
Financing Cash Flow$-1.0M$0$-6.0M$1.0M$0
Net Cash Flow$41.0M$-26.0M$19.0M$-11.0M$57.0M
Free Cash Flow$-14.0M$-29.0M$-54.0M$-48.0M$-63.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.09
EV / EBITDA-5.30
FCF Yield-15.97%
Quick Ratio8.35
Interest Coverage-93.99
Return 1Y-36.76%
Return 3Y-5.53%
Return 5Y33.99%

Ownership

Insiders Held3.51%
Institutions Held38.98%
Institutions Float Held40.40%
Institutional HolderSharesReport Date
Eqt Fund Management S.a R.l.5,900,2942026-03-31
Gildi - Lifeyrissjodur2,430,4012026-03-31
Aberdeen Group plc1,746,9462026-03-31
Pivotal bioVenture Partners Investment Advisor, LLC1,680,2832026-03-31
Wellington Management Group, LLP1,345,7282026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
EYPTEyePoint, Inc. $3.40 -1.73% -0.91 $285.06M 0.00%
HROWHarrow, Inc. $29.36 -3.80% -30.94 $1.09B 0.00%
OCULOcular Therapeutix, Inc. $7.54 +0.40% -5.56 $1.65B 0.00%
OKYOOKYO Pharma Limited $1.42 +2.16% -6.15 $54.48M 0.00%
OTLKOutlook Therapeutics, Inc. $0.60 +6.19% -0.32 $111.99M 0.00%

About Oculis Holding AG

Oculis Holding AG is led by CEO Riad Sherif, employs 49 people, headquartered in CH, publicly traded since 2021.

Oculis Holding AG (OCS) stock trades at $8.34 with a market capitalization of $476.79M. The stock is valued at a price-to-earnings (P/E) ratio of -5.17, price-to-book of 2.02, price-to-sales of 1702.08. Over the past 52 weeks the stock has ranged between $8.34 and $34.48, and currently trades 75.8% below its 52-week high.

On profitability, Oculis Holding AG generates a return on equity (ROE) of -42.92%, return on capital employed of -39.20%, an operating margin of -167.41%, a net profit margin of -188.61%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides